Evidence map›Paper›PMID 40843359›Full record

ArticleCancer drug resistance (Alhambra, Calif.)2025

Integrated multi-omics profiling of immune microenvironment and drug resistance signatures for precision prognosis in prostate cancer.

Chao Li, Longxiang Wu, Bowen Zhong, Yu Gan, Lei Zhou, Shuo Tan, Weibin Hou, Kun Yao, Bingzhi Wang, Zhenyu Ou and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer drug resistance (Alhambra, Calif.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Chao LiDepartment of Urology, The Third Xiangya Hospital, Central South University, Changsha 410013, Hunan, China.
Longxiang WuDepartment of Urology, Xiangya Hospital, Central South University, Changsha 410008, Hunan, China.
Bowen ZhongDepartment of Urology, Xiangya Hospital, Central South University, Changsha 410008, Hunan, China.
Yu GanDepartment of Urology, Xiangya Hospital, Central South University, Changsha 410008, Hunan, China.
Lei ZhouDepartment of Urology, The Third Xiangya Hospital, Central South University, Changsha 410013, Hunan, China.
Shuo TanDepartment of Urology, The Third Xiangya Hospital, Central South University, Changsha 410013, Hunan, China.
Weibin HouDepartment of Urology, The Third Xiangya Hospital, Central South University, Changsha 410013, Hunan, China.
Kun YaoDepartment of Urology, The Third Xiangya Hospital, Central South University, Changsha 410013, Hunan, China.
Bingzhi WangDepartment of Urology, The Third Xiangya Hospital, Central South University, Changsha 410013, Hunan, China.
Zhenyu OuDepartment of Urology, Xiangya Hospital, Central South University, Changsha 410008, Hunan, China.
Shengwang ZhangDepartment of Radiology, The Third Xiangya Hospital, Central South University, Changsha 410013, Hunan, China.
Wei XiongDepartment of Urology, The Third Xiangya Hospital, Central South University, Changsha 410013, Hunan, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

drug resistanceimmunotherapyprognostic modelprostate cancerTumor microenvironment

Identifiers

PMID40843359
PMCPMC12366425

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.